Current role of thalidomide in cancer treatment

被引：63

作者：

Thomas, DA ^{[1
]}

Kantarjian, HM ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2000年 / 12卷 / 06期

关键词：

D O I：

10.1097/00001622-200011000-00009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide (Thalidomid, Celgene, Warren, NJ) is a putative anti-angiogenesis and immunomodulatory agent that has demonstrated activity in various dermatologic and rheumatologic conditions in addition to Crohn's disease. The biologic effects of thalidomide and the clinical trials conducted in solid tumors, hematologic malignancies, chronic graft-versus-host disease (GVHD), and cancer-related cachexia are reviewed. A summary of the preliminary results of ongoing clinical trials is presented, and the future directions of thalidomide research in the oncology are discussed. Curr Opin Oncol 2000, 12:564-573 (C) 2000 Lippincott Williams & Wilkins, Inc.

引用

页码：564 / 573

页数：10

共 95 条

[21]

DIMOPOULOS M, 2000, P AN M AM SOC CLIN, V19, pA27

[22] Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells [J].

Dixon, SC ;

Kruger, EA ;

Bauer, KS ;

Figg, WD .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 43 (Suppl 1) :S78-S84

[23] Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium [J].

Dunzendorfer, S ;

Schratzberger, P ;

Reinisch, N ;

Kahler, CM ;

Wiedermann, CJ .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (05) :529-535

[24] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].

Eisen, T ;

Boshoff, C ;

Mak, I ;

Sapunar, F ;

Vaughan, MM ;

Pyle, L ;

Johnston, SRD ;

Ahern, R ;

Smith, IE ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817

[25] Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre [J].

Fife, K ;

Howard, MR ;

Gracie, F ;

Phillips, RH ;

Bower, M .

INTERNATIONAL JOURNAL OF STD & AIDS, 1998, 9 (12) :751-755

[26]

FIGG WE, 1999, CANC INVEST, V18, pA81

[27] Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas [J].

Fine, HA ;

Figg, WD ;

Jaeckle, K ;

Wen, PY ;

Kyritsis, AP ;

Loeffler, JS ;

Levin, VA ;

Black, PM ;

Kaplan, R ;

Pluda, JM ;

Yung, WKA .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :708-715

[28]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[29] THALIDOMIDE NEUROPATHY - A CLINICAL ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FOLLOW-UP STUDY [J].

FULLERTON, PM ;

OSULLIVA.DJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1968, 31 (06) :543-+

[30] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].

Geitz, H ;

Handt, S ;

Zwingenberger, K .

IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221

← 1 2 3 4 5 6 7 8 9 10 →